| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $6.8M | -68.4% |
| SG&A Expense | $6.9M | -4.8% |
| Operating Income | -$13.7M | +52.4% |
| Pre-tax Income | -$13.0M | +53.0% |
| Income Tax | $0 | — |
| Net Income | -$13.0M | +53.0% |
| EPS (Basic) | -$7.35 | -106.5% |
| EPS (Diluted) | -$7.35 | -106.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $10.3M | -35.8% |
| Current Assets | $10.9M | -32.3% |
| Total Assets | $11.1M | -31.6% |
| Current Liabilities | $5.6M | -31.7% |
| Total Liabilities | $5.8M | -30.5% |
| Stockholders' Equity | $5.3M | -32.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$15.7M | +36.5% |
| Capital Expenditures | $2K | -75.0% |
| Investing Cash Flow | -$2K | +75.0% |
| Financing Cash Flow | $10.0M | -45.6% |
| Free Cash Flow | -$15.7M | +36.5% |